0000950170-24-007559.txt : 20240125 0000950170-24-007559.hdr.sgml : 20240125 20240125175059 ACCESSION NUMBER: 0000950170-24-007559 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240123 FILED AS OF DATE: 20240125 DATE AS OF CHANGE: 20240125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Waltermire Robert E. CENTRAL INDEX KEY: 0001876996 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33277 FILM NUMBER: 24563442 MAIL ADDRESS: STREET 1: FOUR TOWER BRIDGE, 200 BARR HARBOR DRIVE STREET 2: SUITE 200 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MADRIGAL PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001157601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 BUSINESS PHONE: 404-380-9263 MAIL ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 FORMER COMPANY: FORMER CONFORMED NAME: SYNTA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20010815 4 1 ownership.xml 4 X0508 4 2024-01-23 0001157601 MADRIGAL PHARMACEUTICALS, INC. MDGL 0001876996 Waltermire Robert E. C/O MADRIGAL PHARMACEUTICALS, INC. 200 BARR HARBOR DRIVE, SUITE 200 WEST CONSHOHOCKEN PA 19428 false true false false Senior VP, Chief Pharma Dev. false Common Stock 2024-01-23 4 A false 1419 0 A 6536 D Stock Option (Right to Buy) 229.00 2024-01-23 4 A false 2138 0 A 2031-01-23 Common Stock 2138 2138 D Market Stock Unit 2024-01-23 4 A false 1419 0 A Common Stock 1419 1419 D Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date. The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026. **As attorney-in-fact for Reporting Person /s/ Brian J. Lynch** 2024-01-25